ArticleSisli Etfal Hastanesi tip bulteni2026
Morphea Triggered by COVID-19 Vaccination.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the onset of the COVID-19 pandemic in 2019, various vaccines have been developed to control its spread. Initially, conventional inactivated virus vaccines, such as CoronaVac (Sinovac), were introduced, followed by more advanced mRNA-based vaccines, such as BNT162b2 (Pfizer-BioNTech). COVID-19 vaccines have been associated with several adverse effects, particularly dermatological manifestations. Morphea, also known as localized scleroderma, is an inflammatory and sclerosing skin disease that leads to sclerosis and loss of skin elasticity. Genetic and environmental factors, along with immune dysregulation, are thought to play a role in its pathogenesis. We report a case of morphea in a 72-year-old woman who developed localized skin lesions at the vaccination site following CoronaVac administration. To the best of our knowledge, this is the first reported case of morphea potentially triggered by CoronaVac.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.